Bayer and thermo fisher scientific collaborate to increase patient access to precision cancer medicines

Berlin & carlsbad, calif.--(business wire)--bayer ag and thermo fisher scientific inc. today announced a collaboration to develop next-generation sequencing (ngs)-based companion diagnostic assays (cdx) together. these will help identify patients who may benefit from bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. the cdx will be developed using thermo fisher's oncomine dx express test* on the ion torrent genexus dx sy.
TMO Ratings Summary
TMO Quant Ranking